{"entity":"gilead-sciences","id":"ent_gilead-sciences","name":"Gilead Sciences","wikidata":"Q663596","page":"https://asof.is/record/gilead-sciences","summary":"As of November 12, 2025, Gilead Sciences was an American biopharmaceutical company, headquartered in Foster City. It reported revenue of $28.75B for the period ended December 31, 2024.","title":"Gilead Sciences: revenue $28.75B","key_facts":[{"label":"CFO","value":"Andrew D. Dickinson","claim":"clm_012FF580C6B9"},{"label":"Headquarters","value":"Foster City","claim":"clm_3AA77CFFBA18"},{"label":"Revenue","value":"$28.75B","recorded":"28,754,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_766F0DC2656D"},{"label":"Ticker","value":"GILD · Nasdaq","claim":"clm_ACCCAF058EE1"}],"faq":[{"question":"Where is Gilead Sciences headquartered?","answer":"Foster City."},{"question":"What is Gilead Sciences's revenue?","answer":"$28.75B for the period ended December 31, 2024."}],"as_of":"2025-11-12","known_by":null,"since":null,"fact_pages":[{"predicate":"cfo","page":"https://asof.is/record/gilead-sciences/cfo","md":"https://asof.is/record/gilead-sciences/cfo.md","json":"https://asof.is/v1/entities/gilead-sciences/cfo"},{"predicate":"board_member","page":"https://asof.is/record/gilead-sciences/board_member","md":"https://asof.is/record/gilead-sciences/board_member.md","json":"https://asof.is/v1/entities/gilead-sciences/board_member"},{"predicate":"headquarters","page":"https://asof.is/record/gilead-sciences/headquarters","md":"https://asof.is/record/gilead-sciences/headquarters.md","json":"https://asof.is/v1/entities/gilead-sciences/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/gilead-sciences/revenue","md":"https://asof.is/record/gilead-sciences/revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/revenue"},{"predicate":"net_income","page":"https://asof.is/record/gilead-sciences/net_income","md":"https://asof.is/record/gilead-sciences/net_income.md","json":"https://asof.is/v1/entities/gilead-sciences/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/gilead-sciences/operating_income","md":"https://asof.is/record/gilead-sciences/operating_income.md","json":"https://asof.is/v1/entities/gilead-sciences/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/gilead-sciences/quarterly_revenue","md":"https://asof.is/record/gilead-sciences/quarterly_revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/quarterly_revenue"},{"predicate":"country","page":"https://asof.is/record/gilead-sciences/country","md":"https://asof.is/record/gilead-sciences/country.md","json":"https://asof.is/v1/entities/gilead-sciences/country"}],"products":[],"coverage":{"entity":"gilead-sciences","name":"Gilead Sciences","kind":"organization","sources":[{"source":"wikidata","item":"Q663596","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":882095,"ticker":"GILD","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":557,"open":45,"retracted":0,"first":"1987-06-01","predicates":{"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"total_assets":{"claims":71,"open":1,"kind":"fact"},"operating_income":{"claims":19,"open":1,"kind":"fact"},"produces":{"claims":17,"open":17,"kind":"list"},"quarterly_operating_income":{"claims":56,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":51,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":25,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"board_member":{"claims":1,"open":1,"kind":"list"},"cik":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"country":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"agreement":{"claims":2,"open":2,"kind":"event"},"website":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"research_and_development":{"claims":9,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"subsidiary":{"claims":1,"open":1,"kind":"list"},"registrant_name":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":536,"last_added":"2026-11-12","last_checked":"2026-11-12","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":21,"last_added":"2026-11-08","last_checked":"2026-11-11","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_BEFBDF4F70C1","predicate":"agreement","value":"CymaBay Therapeutics, Inc.","valid_from":"2024-02-11","valid_to":null,"published":"2024-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences agreement: CymaBay Therapeutics, Inc.\", as of 2024-02-11. Claim clm_BEFBDF4F70C1, https://asof.is/claim/clm_BEFBDF4F70C1, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm.","url":"https://asof.is/claim/clm_BEFBDF4F70C1","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2024-02-12T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On February 11, 2024, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, CymaBay Therapeutics, Inc., a Delaware corporation (the “ Company ”),","url":"https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm"}},{"id":"clm_2838DB8EBBD6","predicate":"board_member","value":"Ted W. Love","valid_from":"2024-02-01","valid_to":null,"published":"2024-02-02","recorded":"2026-11-12","citation":{"plain":"AsOf. \"Gilead Sciences board member: Ted W. Love\", as of 2024-02-01. Claim clm_2838DB8EBBD6, https://asof.is/claim/clm_2838DB8EBBD6, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/0001104659-24-010051-index.htm.","url":"https://asof.is/claim/clm_2838DB8EBBD6","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/0001104659-24-010051-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2024-02-02T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"On February 1, 2024, at a meeting of the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”), the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to serve on the Board","url":"https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/0001104659-24-010051-index.htm"}},{"id":"clm_7B68B20F3E17","predicate":"cash_and_equivalents","value":"5,412,000,000 United States dollar","valid_from":"2022-12-31","valid_to":null,"published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 5,412,000,000 United States dollar\", as of 2022-12-31. Claim clm_7B68B20F3E17, https://asof.is/claim/clm_7B68B20F3E17, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_7B68B20F3E17","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_012FF580C6B9","predicate":"cfo","value":"Andrew D. Dickinson","valid_from":null,"undated":true,"valid_to":null,"published":"2026-03-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cfo: Andrew D. Dickinson\", undated. Claim clm_012FF580C6B9, https://asof.is/claim/clm_012FF580C6B9, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm.","url":"https://asof.is/claim/clm_012FF580C6B9","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Andrew D. Dickinson Age: 56 Joined Gilead: 2016 Position: ► Chief Financial Officer","url":"https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm"}},{"id":"clm_3A93D2D56CBA","predicate":"cik","value":"0000882095","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cik: 0000882095\", undated. Claim clm_3A93D2D56CBA, https://asof.is/claim/clm_3A93D2D56CBA, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_3A93D2D56CBA","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4F6F32D97D56","predicate":"country","value":"United States","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences country: United States\", undated. Claim clm_4F6F32D97D56, https://asof.is/claim/clm_4F6F32D97D56, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_4F6F32D97D56","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.lobbyfacts.eu/datacard/gilead-sciences?rid=258845020786-10","tier":"secondary","publisher":null,"published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Address Head Office 333 LakesideFoster City California CA94404 UNITED STATES","url":"https://www.lobbyfacts.eu/datacard/gilead-sciences?rid=258845020786-10"}},{"id":"clm_58190642DD33","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences fiscal year end: 12-31\", undated. Claim clm_58190642DD33, https://asof.is/claim/clm_58190642DD33, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_58190642DD33","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_3AA77CFFBA18","predicate":"headquarters","value":"Foster City","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences headquarters: Foster City\", undated. Claim clm_3AA77CFFBA18, https://asof.is/claim/clm_3AA77CFFBA18, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_3AA77CFFBA18","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_79DB7756109C","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences listed on: Nasdaq\", undated. Claim clm_79DB7756109C, https://asof.is/claim/clm_79DB7756109C, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_79DB7756109C","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_D66A9204BCB4","predicate":"net_income","value":"480,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 480,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_D66A9204BCB4, https://asof.is/claim/clm_D66A9204BCB4, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_D66A9204BCB4","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_075AC6F097D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_9D8D94D516C5","predicate":"operating_income","value":"1,662,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 1,662,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9D8D94D516C5, https://asof.is/claim/clm_9D8D94D516C5, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_9D8D94D516C5","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_44AE227A69DA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_E57D81DB0934","predicate":"produces","value":"AmBisome","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: AmBisome\", undated. Claim clm_E57D81DB0934, https://asof.is/claim/clm_E57D81DB0934, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm.","url":"https://asof.is/claim/clm_E57D81DB0934","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"La Verne, California: We manufacture AmBisome and also package and label the majority of our commercial products for distribution to the Americas and the Pacific Rim.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm"}},{"id":"clm_02AE8BF681FF","predicate":"produces","value":"Descovy","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Descovy\", undated. Claim clm_02AE8BF681FF, https://asof.is/claim/clm_02AE8BF681FF, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_02AE8BF681FF","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Descovy is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age or older. Descovy is a fixed-dose combination of our antiretroviral medications, emtricitabine and TAF.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_1415C5129015","predicate":"produces","value":"Harvoni","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Harvoni\", undated. Claim clm_1415C5129015, https://asof.is/claim/clm_1415C5129015, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm.","url":"https://asof.is/claim/clm_1415C5129015","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® , Descovy ® , Descovy for PrEP ® , Emtriva ® , Epclusa ® , Eviplera ® , Genvoya ® , Harvoni ® ,","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm"}},{"id":"clm_17ADCC9F3432","predicate":"produces","value":"Viread","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Viread\", undated. Claim clm_17ADCC9F3432, https://asof.is/claim/clm_17ADCC9F3432, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_17ADCC9F3432","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our HBV products, Vemlidy, Viread and Hepsera, face competition from existing therapies for treating patients with HBV.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_1AC53307215A","predicate":"produces","value":"Truvada","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Truvada\", undated. Claim clm_1AC53307215A, https://asof.is/claim/clm_1AC53307215A, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_1AC53307215A","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Truvada (emtricitabine/TDF) is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of our antiretroviral medications, TDF and emtricitabine.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_2D28666F7CDA","predicate":"produces","value":"Ranexa","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Ranexa\", undated. Claim clm_2D28666F7CDA, https://asof.is/claim/clm_2D28666F7CDA, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_2D28666F7CDA","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® /Eviplera ® , Descovy ® , Emtriva ® , Epclusa ® , Genvoya ® , Harvoni ® , Hepsera ® , Letairis ® , Odefsey ® , Ranexa ® ,","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_32CE8FAE712B","predicate":"produces","value":"Genvoya","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Genvoya\", undated. Claim clm_32CE8FAE712B, https://asof.is/claim/clm_32CE8FAE712B, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_32CE8FAE712B","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® /Eviplera ® , Descovy ® , Emtriva ® , Epclusa ® , Genvoya ® , Harvoni ® ,","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_34D82F160E3A","predicate":"produces","value":"Vosevi","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Vosevi\", undated. Claim clm_34D82F160E3A, https://asof.is/claim/clm_34D82F160E3A, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_34D82F160E3A","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® /Eviplera ® , Descovy ® , Emtriva ® , Epclusa ® , Genvoya ® , Harvoni ® , Hepsera ® , Letairis ® , Odefsey ® , Ranexa ® , Sovaldi ® , Stribild ® , Truvada ® , Tybost ® , Vemlidy ® , Viread ® , Vo","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_4957ADDA4140","predicate":"produces","value":"Eviplera","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Eviplera\", undated. Claim clm_4957ADDA4140, https://asof.is/claim/clm_4957ADDA4140, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_4957ADDA4140","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_4973D7F4E957","predicate":"produces","value":"Odefsey","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Odefsey\", undated. Claim clm_4973D7F4E957, https://asof.is/claim/clm_4973D7F4E957, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_4973D7F4E957","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_61DF48AD78AD","predicate":"produces","value":"Letairis","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Letairis\", undated. Claim clm_61DF48AD78AD, https://asof.is/claim/clm_61DF48AD78AD, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm.","url":"https://asof.is/claim/clm_61DF48AD78AD","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® , Descovy ® , Descovy for PrEP ® , Emtriva ® , Epclusa ® , Eviplera ® , Genvoya ® , Harvoni ® , Hepcludex ® , Hepsera ® , Jyseleca ® , Letairis ® ,","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm"}},{"id":"clm_66A870C2CD56","predicate":"produces","value":"Atripla","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Atripla\", undated. Claim clm_66A870C2CD56, https://asof.is/claim/clm_66A870C2CD56, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_66A870C2CD56","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"We may continue to purchase efavirenz from BMS as needed to continue manufacturing Atripla for the United States and Canada markets.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_677E45C1E417","predicate":"produces","value":"Tybost","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Tybost\", undated. Claim clm_677E45C1E417, https://asof.is/claim/clm_677E45C1E417, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_677E45C1E417","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® /Eviplera ® , Descovy ® , Emtriva ® , Epclusa ® , Genvoya ® , Harvoni ® , Hepsera ® , Letairis ® , Odefsey ® , Ranexa ® , Sovaldi ® , Stribild ® , Truvada ® , Tybost ®","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_6E62E9EA4BA4","predicate":"produces","value":"Epclusa","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Epclusa\", undated. Claim clm_6E62E9EA4BA4, https://asof.is/claim/clm_6E62E9EA4BA4, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm.","url":"https://asof.is/claim/clm_6E62E9EA4BA4","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® , Descovy ® , Descovy for PrEP ® , Emtriva ® , Epclusa ® ,","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm"}},{"id":"clm_6F3C1A89CF3B","predicate":"produces","value":"Stribild","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Stribild\", undated. Claim clm_6F3C1A89CF3B, https://asof.is/claim/clm_6F3C1A89CF3B, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_6F3C1A89CF3B","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"We receive a substantial portion of our revenue from sales of our products for the treatment of HIV infection, which include Genvoya, Truvada, Atripla, Descovy, Stribild, Odefsey and Complera/Eviplera.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_952713EE6AA9","predicate":"produces","value":"Emtriva","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Emtriva\", undated. Claim clm_952713EE6AA9, https://asof.is/claim/clm_952713EE6AA9, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_952713EE6AA9","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® /Eviplera ® , Descovy ® , Emtriva ® , Epclusa ® ,","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_F96CA553BE60","predicate":"produces","value":"Complera","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences produces: Complera\", undated. Claim clm_F96CA553BE60, https://asof.is/claim/clm_F96CA553BE60, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_F96CA553BE60","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_8C716505DCB2","predicate":"quarterly_net_income","value":"3,052,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,052,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8C716505DCB2, https://asof.is/claim/clm_8C716505DCB2, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_8C716505DCB2","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_24FF1FC3A935","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_E88E046C7258","predicate":"quarterly_operating_income","value":"3,327,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,327,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_E88E046C7258, https://asof.is/claim/clm_E88E046C7258, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_E88E046C7258","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3305AD308056","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_46B555B900FF","predicate":"quarterly_research_and_development","value":"1,101,000,000 United States dollar","valid_from":"2020-03-31","valid_to":null,"published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,101,000,000 United States dollar\", as of 2020-03-31. Claim clm_46B555B900FF, https://asof.is/claim/clm_46B555B900FF, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_46B555B900FF","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_3A5203A42518","predicate":"quarterly_revenue","value":"7,769,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,769,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_3A5203A42518, https://asof.is/claim/clm_3A5203A42518, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_3A5203A42518","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B00A751741D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_B758636654A0","predicate":"registrant_name","value":"GILEAD SCIENCES, INC.","valid_from":"1994-02-14","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences registrant name: GILEAD SCIENCES, INC.\", as of 1994-02-14. Claim clm_B758636654A0, https://asof.is/claim/clm_B758636654A0, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_B758636654A0","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_EF2F795524C5","predicate":"research_and_development","value":"9,106,000,000 United States dollar","valid_from":"2019-12-31","valid_to":null,"published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 9,106,000,000 United States dollar\", as of 2019-12-31. Claim clm_EF2F795524C5, https://asof.is/claim/clm_EF2F795524C5, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_EF2F795524C5","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_766F0DC2656D","predicate":"revenue","value":"28,754,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 28,754,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_766F0DC2656D, https://asof.is/claim/clm_766F0DC2656D, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_766F0DC2656D","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5E2D1C5DC1DC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_5E452E3F3A54","predicate":"shares_outstanding","value":"1,240,679,623 shares","valid_from":"2025-10-31","valid_to":"2026-02-13","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,679,623 shares\", as of 2025-10-31 (until 2026-02-13). Claim clm_5E452E3F3A54, https://asof.is/claim/clm_5E452E3F3A54, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5E452E3F3A54","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E2DB5E0B53B4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_44B0DF6C61E1","predicate":"sic_industry","value":"Biological Products, (No Diagnostic Substances) (2836)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences sic industry: Biological Products, (No Diagnostic Substances) (2836)\", undated. Claim clm_44B0DF6C61E1, https://asof.is/claim/clm_44B0DF6C61E1, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_44B0DF6C61E1","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_433BC2407C2F","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences state of incorporation: DE\", undated. Claim clm_433BC2407C2F, https://asof.is/claim/clm_433BC2407C2F, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_433BC2407C2F","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B6ADB7E79288","predicate":"subsidiary","value":"Kite Pharma","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences subsidiary: Kite Pharma\", undated. Claim clm_B6ADB7E79288, https://asof.is/claim/clm_B6ADB7E79288, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_B6ADB7E79288","accessed":"2026-11-12"},"confidence":0.8,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"On October 3, 2017 (the Acquisition Date), we completed a tender offer for all of the outstanding common stock of Kite Pharma, Inc. (Kite) for $180 per share in cash. As a result, Kite became our wholly-owned subsidiary.","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm"}},{"id":"clm_ACCCAF058EE1","predicate":"ticker","value":"GILD","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences ticker: GILD\", undated. Claim clm_ACCCAF058EE1, https://asof.is/claim/clm_ACCCAF058EE1, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_ACCCAF058EE1","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_5B9243C901AF","predicate":"total_assets","value":"58,533,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 58,533,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_5B9243C901AF, https://asof.is/claim/clm_5B9243C901AF, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5B9243C901AF","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_06C160F8C3A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_B2A4004D2607","predicate":"total_equity","value":"21,540,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,540,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_B2A4004D2607, https://asof.is/claim/clm_B2A4004D2607, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_B2A4004D2607","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_994B784F55A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_6FC170F46335","predicate":"website","value":"https://www.gilead.com/","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences website: https://www.gilead.com/\", undated. Claim clm_6FC170F46335, https://asof.is/claim/clm_6FC170F46335, accessed 2026-11-12. Source: https://www.wikidata.org/wiki/Q663596.","url":"https://asof.is/claim/clm_6FC170F46335","accessed":"2026-11-12"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-11","quote":"Gilead Sciences.","url":"https://www.gilead.com/"}},{"id":"clm_B694320241BE","predicate":"x_username","value":"GileadSciences","valid_from":"2011-06-02","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences x username: GileadSciences\", as of 2011-06-02. Claim clm_B694320241BE, https://asof.is/claim/clm_B694320241BE, accessed 2026-11-12. Source: https://www.wikidata.org/wiki/Q663596.","url":"https://asof.is/claim/clm_B694320241BE","accessed":"2026-11-12"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/GileadSciences","url":"https://www.gilead.com/"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}